Stockscreener 앱 받기
0.7298
0.38%
-0.0028
전일 마감가:
$0.7326
열려 있는:
$0.76
하루 거래량:
420.60K
Relative Volume:
0.56
시가총액:
$69.40M
수익:
순이익/손실:
$-19.58M
주가수익비율:
-2.832
EPS:
-0.2577
순현금흐름:
$-20.25M
1주 성능:
-16.78%
1개월 성능:
-28.45%
6개월 성능:
-34.25%
1년 성능:
-60.55%
1일 변동 폭
$0.7134
$0.7874
1주일 범위
$0.7134
$0.93
52주 변동 폭
$0.5501
$1.9999
Cognition Therapeutics Inc Stock (CGTX) Company Profile
명칭
Cognition Therapeutics Inc
전화
412-481-2210
주소
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.7298 | 69.40M | 0 | -19.58M | -20.25M | -0.2577 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | 개시 | B. Riley Securities | Buy |
| 2021-11-03 | 개시 | Oppenheimer | Outperform |
Cognition Therapeutics Inc 주식(CGTX)의 최신 뉴스
A drug patent runs to 2045. FDA approval may allow up to five more years. - Stock Titan
Cognition Therapeutics Stock Price Forecast. Should You Buy CGTX? - StockInvest.us
Cognition Therapeutics Schedules FDA Type C Meeting to Discuss Phase 3 Trial Endpoint for Zervimesine in Dementia with Lewy Bodies - Quiver Quantitative
An experimental drug slowed the progression of hallucinations and delusions by 89% vs. placebo. - Stock Titan
FDA aligns with Cognition on pivotal DLB psychosis trial - scanx.trade
An Alzheimer's drug will be discussed Sept. 15 by Cognition Therapeutics - Stock Titan
MU: Micron Technology Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Cognition (CGTX) Today: Moves 1.14% Lower to $0.98 for the Current Session; Technical Setup: the $0.93 to $1.03 Range Remains in Focus under the Current SnapshotIPO Entry Watch - vinanet.vn
Cognition (CGTX) Earnings Report: Reported EPS Tops Expectations; Market Reaction: Shares Move 0.22% Lower in the Latest ReadingPreliminary Results - vinanet.vn
Cognition Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
HC Wainwright Has Bullish Estimate for CGTX Q3 Earnings - MarketBeat
Cognition Therapeutics (CGTX) Slips 2.9% to $1.01, Nears Support at $0.96Dealer Delta - vinanet.vn
Cognition Therapeutics (CGTX) Slips 2.9% to $1.01, Nears Support at $0.96Money Flow Index - dars.gov.et
Cognition Therapeutics (CGTX) Slips 2.9% to $1.01, Nears Support at $0.96Point of Control - careplusvn.com
Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Lowered by Wall Street Zen - MarketBeat
CGTX FY2026 EPS Forecast Raised by Brookline Capital Markets - MarketBeat
Cognition Therapeutics Stock (CGTX) Opinions on biotech upside speculation - Quiver Quantitative
Cognition Therapeutics (NASDAQ:CGTX) Releases Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Cognition Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cognition Therapeutics, Inc. (CGTX) latest stock news and headlines - Yahoo Finance UK
Cognition Therapeutics Inc Q2 2026: Net loss $(3.9M), EPS $(0.04) — 10-Q Summary - TradingView
Cognition Therapeutics Inc (CGTX) Stock News Today - TradingKey
Cognition Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cognition Therapeutics Q2 EPS beats estimate as R&D cuts narrow losses - scanx.trade
Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Cognition Therapeutics reports Q2 2026 net loss $3.9M, cash $34.8M; plans Phase 3 in DLB psychosis - TradingView
Cognition Therapeutics Q2 net loss narrows on lower R&D costs - TradingView
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update - Yahoo Finance
Cognition plans mid-2027 dementia trial; patent could extend to 2045 - Stock Titan
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update - GlobeNewswire
Cognition Therapeutics Inc (CGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cognition Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
CGTX News | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
Cognition Therapeutics (CGTX) Edges Higher as Traders Eye Key Resistance LevelsAdvance Decline Volume - vinanet.vn
Cognition Therapeutics (NASDAQ:CGTX) Trading Up 3.3%Time to Buy? - MarketBeat
Cognition Therapeutics Inc (CGTX) Balance Sheet - TradingKey
Cognition Therapeutics Inc (CGTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CGTX|Cognition Therapeutics Inc|Price:1.020|Chg%:-0.040 - tradingkey.com
Cognition Therapeutics Inc (CGTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cognition Therapeutics Inc (CGTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cognition Therapeutics Inc (CGTX) Cash Flow - TradingKey
Cognition Therapeutics Inc (CGTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cognition Therapeutics Inc (CGTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CGTX|Cognition Therapeutics Inc|Price:0.919|Chg%:-0.041 - TradingKey
Cognition Therapeutics Inc (CGTX) Income Statement - TradingKey
Cognition Therapeutics, Inc. Revenue Breakdown – NASDAQ:CGTX - TradingView
Cognition Therapeutics Inc (CGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CGTX|Cognition Therapeutics Inc|Price:0.982|Chg%:-0.038 - TradingKey
CGTX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Progress in Alzheimer’s PipelineRevenue Growth Outlook - vinanet.vn
Cognition Therapeutics (CGTX) Slips 4% as Support Level Comes Into FocusRunaway Gap - vinanet.vn
Cognition Therapeutics Inc (CGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cognition Therapeutics Inc 주식 (CGTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ricciardi Lisa | CEO & President |
Apr 16 '26 |
Buy |
1.10 |
9,175 |
10,092 |
1,715,851 |
| Caggiano Anthony | Chief Medical Officer |
Apr 16 '26 |
Buy |
1.11 |
10,000 |
11,100 |
874,906 |
4.22%
자본화:
|
볼륨(24시간):